Phosphono substituted tetrazole derivatives as endothelin-converting enzyme inhibitors

Author:  

Publisher: Informa Healthcare

ISSN: 1354-3776

Source: Expert Opinion on Therapeutic Patents, Vol.7, Iss.3, 1997-03, pp. : 277-280

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

This patent, from Ciba-Geigy AG, discloses a series of phosphono substituted tetrazole derivatives as ECE inhibitors and claims them as useful in the treatment of pulmonary hypertension, cerebral ischaemia, subarachnoid haemorrhage, renal failure, atherosclerosis, cerebral vasospasm, arterial hypertrophy, restenosis, arrhythmia and myocardial infarction, endotoxic shock, pre-eclampsia, diabetes (e.g., diabetic nephropathy) and Raynaud's disease